688062 邁威生物
按盤價 
26.580 -0.520 (-1.919%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 312,642 | 209.04% | 662,516 | 199,782 | 127,836 | 27,728 | |
| 減：營業總成本 | 824,539 | 22.75% | 1,634,418 | 1,259,798 | 1,175,895 | 993,419 | |
| 其中:營業成本 | 76,715 | 256.02% | 64,464 | 28,952 | 1,370 | 71 | |
| 財務費用 | 68,990 | 90.24% | 87,067 | 36,726 | (33,411) | (34,764) | |
| 資產減值損失 | (481) | -93.74% | (11,264) | (5,527) | (9,488) | (1,940) | |
| 公允價值變動收益 | 55 | 203.83% | 1,122 | 493 | (3,043) | 1,082 | |
| 投資收益 | (5,045) | 76.04% | (9,602) | (4,219) | (1,649) | 714 | |
| 其中：對聯營企業和合營企業的投資收益 | (6,104) | 93.79% | (10,562) | (7,058) | (2,594) | (476) | |
| 營業利潤 | (516,869) | -6.44% | (955,318) | (1,043,480) | (1,052,579) | (958,139) | |
| 利潤總額 | (523,815) | -5.14% | (956,394) | (1,047,471) | (1,055,288) | (958,126) | |
| 減：所得稅費用 | 389 | 618.68% | 15,864 | (907) | 3,524 | -- | |
| 淨利潤 | (524,205) | -5.07% | (972,258) | (1,046,565) | (1,058,811) | (958,126) | |
| 減：非控股權益 | (2,497) | 174.11% | (2,924) | (2,645) | (5,379) | (2,891) | |
| 股東淨利潤 | (521,708) | -5.37% | (969,334) | (1,043,919) | (1,053,433) | (955,235) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -1.260 | -8.70% | -2.430 | -2.610 | -2.640 | -2.440 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 1.955 | -4.49% | 0.875 | 3.926 | 6.466 | 8.798 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 08/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
